Clinical trials
32 active studies led by Beijing Biotech, of 32 in all
Source: ClinicalTrials.gov, Studies with Beijing Biotech (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
- 0Reports naming them
- 7Markets in public records
- 0Regions & countries
- 32Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by Beijing Biotech or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public data on Beijing Biotech
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
See them on ClinicalTrials.gov (opens in a new tab)
US drug approvals
1 approvals with a product on the US market
- Fluvastatin Sodium ANDA209397 · approved 26 Apr 2021
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
Trials over time
Studies Beijing Biotech leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with Beijing Biotech or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets where public records show them
Markets we cover where free public records show Beijing Biotech: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets Beijing Biotech is in.
From our blog
Stories on the topics Beijing Biotech works in.
Brain Cancer Diagnosis: Imaging and New Biomarkers
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
Bioinformatics: Making Sense of Health Data
Sequencing a human genome fell from about $50 million in 2003 to under $1,500 by late 2015. Bioinformatics…
Read
Dermatology Diagnostics: AI and Skin Health
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Read